Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director · President and CEO | January 06, 2026 | January 08, 2026 |
| Surface Oncology, Inc.SURF · Entity 109857 | Director | June 28, 2022 | June 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 323,530 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Sale · Disposed 23,766 · Balance 323,530 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
Surface Oncology, Inc.
Report date June 28, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2032-06-28 | Direct | 48,000 |
Reported balance
After 2022-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-28 · Grant · Acquired 48,000 · Balance 48,000 F1: 50% of the Options shall vest on June 28, 2023, and the remainder of the Options shall vest in equal monthly installments over the following twelve months, such that all of the Options shall be vested on June 28, 2024, subject to the Reporting Person's continued service relationship with the Company on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the Options shall vest on June 28, 2023, and the remainder of the Options shall vest in equal monthly installments over the following twelve months, such that all of the Options shall be vested on June 28, 2024, subject to the Reporting Person's continued service relationship with the Company on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 8, 2026 16:20 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 23,766 | $6.82 | $162,076.99 |
DisclosureSEC source: 0001453687-26-000047 · wk-form4_1767907199.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,530 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 415,700 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001453687-26-000038 · wk-form4_1767734357.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,700 Underlying: Common Stock · 415,700 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 143,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-26-000038 · wk-form4_1767734357.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,296 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 20:04 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 8,708 | $16.83 | $146,574.80 |
DisclosureSEC source: 0001453687-25-000036 · wk-form4_1736298292.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,096 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 20:04 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 8,563 | $16.72 | $143,189.63 |
DisclosureSEC source: 0001453687-25-000036 · wk-form4_1736298292.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,804 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:21 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 169,100 | $0.00 Strike: $16.93 | $0.00 |
DisclosureSEC source: 0001453687-25-000028 · wk-form4_1736198480.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,100 Underlying: Common Stock · 169,100 shares Expires 2035-01-01 F3 · derivative.exercise_date: This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:21 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-25-000028 · wk-form4_1736198480.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,367 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. F2 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 17:07 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 5,971,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001453687-24-000025 · wk-form4_1704406045.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,971,000 Underlying: Common Stock · 5,971,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 17:07 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 4,654,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-24-000025 · wk-form4_1704406045.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,916,056 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,275,000 | $0.93 Strike: $1.13 | $1,185,750.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 13 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,275,000 shares Expires 2033-01-01 F13 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on January 2, 2024 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger, in exchange for a cash payment of $1,185,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,056,100 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 12 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,056,100 shares Expires 2032-01-02 F12 · price: This option, which provided for vesting as to 25% of the shares on January 3, 2023 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F12 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on January 3, 2023 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 163,000 | Not disclosed Strike: $4.32 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 11 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,000 shares Expires 2031-09-23 F11 · price: This option, which provided for vesting as to 25% of the shares on September 24, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F11 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on September 24, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 670,000 | Not disclosed Strike: $2.99 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 10 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 670,000 shares Expires 2031-01-03 F10 · price: This option, which provided for vesting as to 25% of the shares on January 4, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F10 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on January 4, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 9 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2030-06-30 F9 · price: This option, which provided for vesting as to 25% of the shares on July 1, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F9 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on July 1, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 600,000 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 8 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2030-01-01 F8 · price: This option, which provided for vesting as to 25% of the shares on January 2, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F8 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on January 2, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.31 Strike: $1.75 | $124,000.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 7 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2029-10-06 F7 · derivative.exercise_date: This option, which provided for vesting as to 50% of the shares on October 7, 2020 and the remaining 50% of the shares on October 7, 2021, was canceled in the Merger, in exchange for a cash payment of $124,000, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 330,000 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 6 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 330,000 shares Expires 2029-02-24 F6 · price: This option, which provided for vesting as to 25% of the shares on February 25, 2020 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F6 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on February 25, 2020 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $6.03 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 5 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2028-11-30 F5 · price: This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerCommon Stock | 282,800 | $2.06 | $582,568.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 4 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,956 F4 · shares: This unvested restricted stock, which was granted on January 2, 2023, was canceled in the Merger, in exchange for $582,568, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerCommon Stock | 169,725 | $2.06 | $349,633.50 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,756 F3 · shares: This unvested restricted stock, which was granted on January 3, 2022, was canceled in the Merger, in exchange for $349,633.50, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerCommon Stock | 13,600 | $2.06 | $28,016.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 714,481 F2 · shares: This unvested restricted stock, which was granted on September 24, 2021, was canceled in the Merger, in exchange for $28,016, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerCommon Stock | 55,000 | $2.06 | $113,300.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,081 F1 · shares: This unvested restricted stock, which was granted on January 4, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for $113,300, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 18:01 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 2,932 | $1.06 | $3,107.92 |
DisclosureSEC source: 0001453687-23-000068 · wk-form4_1695765647.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 783,081 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 17:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 77 | $1.12 | $85.86 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 4 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,013 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 17:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 13,396 | $1.13 | $15,128.10 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,090 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 17:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 48 | $1.15 | $54.96 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,486 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 17:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 27,549 | $1.13 | $31,232.30 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,534 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:03 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 1,275,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000022 · wf-form4_167286979042642.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,000 Underlying: Common Stock · 1,275,000 shares Expires 2033-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:03 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 282,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000022 · wf-form4_167286979042642.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,083 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 16:17 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,522 | $1.33 | $6,014.26 |
DisclosureSEC source: 0001453687-22-000147 · wf-form4_167044782270489.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,283 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:24 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000145 · wf-form4_167027547181099.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: This restricted stock unit award is fully vested and has no expiration date F2 · derivative.expiration_date: This restricted stock unit award is fully vested and has no expiration date Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:24 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000145 · wf-form4_167027547181099.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 19:37 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 2,692 | $1.66 | $4,470.07 |
DisclosureSEC source: 0001453687-22-000131 · wf-form4_166458101110775.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,867 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.6604 to $1.6605. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:37 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,768 | $1.85 | $8,810.31 |
DisclosureSEC source: 0001453687-22-000129 · wf-form4_166251104851877.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,559 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.825 to $1.855. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:37 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000129 · wf-form4_166251104851877.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:37 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000129 · wf-form4_166251104851877.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 20:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001209191-22-039976 · doc4.xml · derivative · entry 1 Brunn Carsten · CIK 0001760229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: 50% of the Options shall vest on June 28, 2023, and the remainder of the Options shall vest in equal monthly installments over the following twelve months, such that all of the Options shall be vested on June 28, 2024, subject to the Reporting Person's continued service relationship with the Company on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:44 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000099 · wf-form4_165428903107199.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F2 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:44 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000099 · wf-form4_165428903107199.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 16:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 5,443 | $1.81 | $9,863.26 |
DisclosureSEC source: 0001453687-22-000044 · wf-form4_164634331527341.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,452 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.80 to $1.825. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000044 · wf-form4_164634331527341.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,813 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000044 · wf-form4_164634331527341.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:17 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 13,597 | $3.09 | $41,958.98 |
DisclosureSEC source: 0001453687-22-000031 · wf-form4_164159025635618.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,958 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.99 to $3.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 1,056,100 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000016 · wf-form4_164141830853581.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056,100 Underlying: Common Stock · 1,056,100 shares Expires 2032-01-02 F2 · derivative.exercise_date: This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 226,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000016 · wf-form4_164141830853581.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,555 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 17:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 17,196 | $2.99 | $51,362.73 |
DisclosureSEC source: 0001453687-21-000183 · wf-form4_163952015012703.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,255 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.94 to $3.0201. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 17:06 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000173 · wf-form4_163917398636442.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,451 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 75,000 shares of the Issuer's common stock (the "Performance RSUs"), which were earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. The compensation committee of the board of directors of the Issuer has determined that the second of the performance conditions has been met, and accordingly 37,500 Performance RSUs vested on December 8, 2021, Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 16:28 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,746 | $2.96 | $14,064.77 |
DisclosureSEC source: 0001453687-21-000158 · wf-form4_163856690437223.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,951 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.94 to $2.99. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 16:28 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000158 · wf-form4_163856690437223.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 16:28 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000158 · wf-form4_163856690437223.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.